Tumor regression achieved by encapsulating a moderately soluble drug into a polymeric thermogel

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Ci, Tianyuan ^a   Chen, Liang ^a   Yu, Lin ^a   Ding, Jiandong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; HYDROGEL; IRINOTECAN; MACROGOL DERIVATIVE; NANOCAPSULE; POLY(LACTIDE-CO-GLYCOLIDE)-BLOCK-POLY(ETHYLENE GLYCOL)-BLOCK-POLY(LACTIDE-CO-GLYCOLIDE); POLYESTER;

ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DIFFUSION; HYDROGEL; MOUSE; NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; PARTICLE SIZE; PATHOLOGY; PROCEDURES; RABBIT; REMISSION; SOLUBILITY; TREATMENT OUTCOME; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; CAMPTOTHECIN; CELL LINE, TUMOR; DIFFUSION; HYDROGELS; MICE; MICE, NUDE; NANOCAPSULES; NEOPLASMS, EXPERIMENTAL; PARTICLE SIZE; POLYESTERS; POLYETHYLENE GLYCOLS; RABBITS; REMISSION INDUCTION; SOLUBILITY; TREATMENT OUTCOME;

EID: 84903738092     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep05473     Document Type: Article

References (58)

1. Chabner, B. A. & Roberts, T. G. Timeline - Chemotherapy and the war on cancer. Nat. Rev. Cancer 5, 65-72 (2005).
2. Galmarini, D., Galmarini, C. M. & Galmarini, F. C. Cancer chemotherapy: A critical analysis of its 60 years of history. Crit. Rev. Oncol./Hematol. 84, 181-199 (2012).
3. Braun, M. S. & Seymour, M. T. Balancing the efficacy and toxicity of chemotherapy in colorectal cancer. Ther Adv Med Oncol 3, 43-52 (2011).
4. Anderson, D. G., Burdick, J. A. & Langer, R. Materials science - Smart biomaterials. Science 305, 1923-1924 (2004).
5. Derfus, A. M. et al. Remotely triggered release from magnetic nanoparticles. Adv. Mater. 19, 3932-3936 (2007).
6. Hoffman, A. S. The origins and evolution of ''controlled'' drug delivery systems. J. Control. Release 132, 153-163 (2008).
7. Pitukmanorom, P., Yong, T. H. & Ying, J. Y. Tunable release of proteins with polymer-inorganic nanocomposite microspheres. Adv. Mater. 20, 3504-3509 (2008).
8. Jay, S. M. & Saltzman, W. M. Controlled delivery of VEGF via modulation of alginate microparticle ionic crosslinking. J. Control. Release 134, 26-34 (2009).
9. Zhao, X. H. et al.Active scaffolds for on-demand drug and cell delivery. Proc. Natl. Acad. Sci. U. S. A. 108, 67-72 (2011).
10. Shao, J. W. et al. Photothermal nanodrugs: potential of TNF-gold nanospheres for cancer theranostics. Sci Rep 3, 1293 (2013).
11. Venditto, V. J. & Szoka, F. C. Cancer nanomedicines: So many papers and so few drugs! Adv. Drug Deliv. Rev. 65, 80-88 (2013).
12. Kissel, T., Li, Y. X. & Unger, F. ABA-triblock copolymers from biodegradable polyester A-blocks and hydrophilic poly(ethylene oxide) B-blocks as a candidate for in situ forming hydrogel delivery systems for proteins. Adv. Drug Deliv. Rev. 54, 99-134 (2002).
13. Watanabe, M. et al. Preparation of camptothecin-loaded polymeric micelles and evaluation of their incorporation and circulation stability. Int. J. Pharm. 308, 183-189 (2006).
14. Bae, Y. & Kataoka, K. Intelligent polymeric micelles from functional poly(ethylene glycol)-poly(amino acid) block copolymers. Adv. Drug Deliv. Rev. 61, 768-784 (2009).
15. Kopecek, J. & Kopeckova, P. HPMA copolymers: origins, early developments, present, and future. Adv. Drug Deliv. Rev. 62, 122-149 (2010).
16. Jeong, B., Bae, Y. H., Lee, D. S. & Kim, S. W. Biodegradable block copolymers as injectable drug-delivery systems. Nature 388, 860-862 (1997).
17. Yu, L. & Ding, J. D. Injectable hydrogels as unique biomedical materials. Chem. Soc. Rev. 37, 1473-1481 (2008).
18. Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 6, 789-802 (2006).
19. Lawrence, S. Billion dollar babies - biotech drugs as blockbusters. Nat. Biotechnol. 25, 380-382 (2007).
20. Potmesil, M. Camptothecins- from bench research to hospital wards. Cancer Res. 54, 1431-1439 (1994).
21. Liu, J., Jiang, Z. Z., Zhang, S. M. & Saltzman, W. M. Poly(omegapentadecalactone- co-butylene-co-succinate) nanoparticles as biodegradable carriers for camptothecin delivery. Biomaterials 30, 5707-5719 (2009).
22. Burke, T. G. & Mi, Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J. Med. Chem. 37, 40-46 (1994).
23. Herben, V. M. M. et al. Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors. J. Clin. Oncol. 17, 1897-1905 (1999).
24. Narasimhan, B. & Langer, R. Zero-order release of micro- and macromolecules from polymeric devices: the role of the burst effect. J. Control. Release 47, 13-20 (1997).
25. Huang, X. & Brazel, C. S. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J. Control. Release 73, 121-136 (2001).
26. Rao, V. M.,Haslam, J. L. & Stella, V. J. Controlled and complete release of amodel poorly water-soluble drug, prednisolone, from hydroxypropyl methylcellulose matrix tablets using (SBE)(7 m)-beta-cyclodextrin as a solubilizing agent. J. Pharm. Sci. 90, 807-816 (2001).
27. Lao, L. L., Venkatraman, S. S. & Peppas, N. A. A novel model and experimental analysis of hydrophilic and hydrophobic agent release from biodegradable polymers. J. Biomed. Mater. Res. Part A 90, 1054-1065 (2009).
28. Qiu, Y. & Park, K. Environment-sensitive hydrogels for drug delivery. Adv. Drug Deliv. Rev. 53, 321-339 (2001).
29. Zentner, G. M. et al. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J. Control. Release 72, 203-215 (2001).
30. Choi, S. & Kim, S.W. Controlled release of insulin from injectable biodegradable triblock copolymer depot in ZDF rats. Pharm. Res. 20, 2008-2010 (2003).
31. Van Tomme, S. R. & Hennink, W. E. Biodegradable dextran hydrogels for protein delivery applications. Expert Rev. Med. Devices 4, 147-164 (2007).
32. Elstad, N. L. & Fowers, K. D. OncoGel (ReGel/paclitaxel) - Clinical applications for a novel paclitaxel delivery system. Adv. Drug Deliv. Rev. 61, 785-794 (2009).
33. Chang, G. T., Ci, T. Y., Yu, L. & Ding, J. D. Enhancement of the fraction of the active form of an antitumor drug topotecan via an injectable hydrogel. J. Control. Release 156, 21-27 (2011).
34. Siepmann, J. & Peppas, N. A. Higuchi equation: derivation, applications, use and misuse. Int. J. Pharm. 418, 6-12 (2011).
35. Beretta, G. L. & Zunino, F. Relevance of extracellular and intracellular interactions of camptothecins as determinants of antitumor activity. Biochem. Pharmacol. 74, 1437-1444 (2007).
36. Gupta, E. et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 54, 3723-3725 (1994).
37. Burris, H. A. et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units In vitro. J. Natl. Cancer Inst. 84, 1816-1820 (1992).
38. Mathijssen, R. H. J. et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res. 7, 2182-2194 (2001).
39. Kurita, A. et al. Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion. Cancer Chemother. Pharmacol. 52, 349-360 (2003).
40. Crcarevska,M. S. et al. Definition of formulation design space, in vitro bioactivity and in vivo biodistribution for hydrophilic drug loaded PLGA/PEO-PPO-PEO nanoparticles using OFAT experiments. Eur. J. Pharm. Sci. 49, 65-80 (2013).
41. Tang, Y. Q., Czuczman, P. R., Chung, S. T. & Lewis, A. L. Preservation of the active lactone form of irinotecan using drug eluting beads for the treatment of colorectal cancer metastases. J. Control. Release 127, 70-78 (2008).
42. Yohe, S. T., Herrera, V. L. M., Colson, Y. L. & Grinstaff, M. W. 3D superhydrophobic electrospun meshes as reinforcement materials for sustained local drug delivery against colorectal cancer cells. J. Control. Release 162, 92-101 (2012).
43. Ohe, Y. et al. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J. Natl. Cancer Inst. 84, 972-974 (1992).
44. Li, T., Ci, T. Y., Chen, L., Yu, L. & Ding, J. D. Salt-induced reentrant hydrogel of poly(ethylene glycol)-poly(lactide-co-glycolide) block copolymers. Polym. Chem. 5, 979-991 (2014).
45. Zhang, H., Yu, L. & Ding, J. D. Roles of hydrophilic homopolymers on the hydrophobic-association-induced physical gelling of amphiphilic block copolymers in water. Macromolecules 41, 6493-6499 (2008).
46. He, C. L., Kim, S. W. & Lee, D. S. In situ gelling stimuli-sensitive block copolymer hydrogels for drug delivery. J. Control. Release 127, 189-207 (2008).
47. Moon,H. J., Ko,D. Y., Park, M. H., Joo, M. K. & Jeong, B. Temperature-responsive compounds as in situ gelling biomedical materials. Chem. Soc. Rev. 41, 4860-4883 (2012).
48. Li, K. et al.Along-acting formulation of a polypeptide drug exenatide in treatment of diabetes using an injectable block copolymer hydrogel. Biomaterials 34, 2834-2842 (2013).
49. Zhang, Z. et al. Biodegradable and thermoreversible PCLA-PEG-PCLA hydrogel as a barrier for prevention of post-operative adhesion. Biomaterials 32, 4725-4736 (2011).
50. Yu, L. et al. Poly(lactic acid-co-glycolic acid)-poly(ethylene glycol)-poly(lactic acid-co-glycolic acid) thermogel as a novel submucosal cushion for endoscopic submucosal dissection. Acta Biomater. 10, 1251-1258 (2014).
51. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3-25 (1997).
52. Willett, C. G. et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J. Clin. Oncol. 27, 3020-3026 (2009).
53. Fassberg, J. & Stella, V. J. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci. 81, 676-684 (1992).
54. Ci, T. Y. et al. Effects of amphiphilic block copolymers on the equilibrium lactone fractions of camptothecin analogues at different pHs. Biomater. Sci. 1, 1235-1243 (2013).
55. Ci, T. Y., Li, T., Chang, G. T., Yu, L. & Ding, J. D. Simply mixingwith poly(ethylene glycol) enhances the fraction of the active chemical form of antitumor drugs of camptothecin family. J. Control. Release 169, 329-335 (2013).
56. Ci, T. Y. et al. Effects of ''mature micelle'' formation of Pluronic P123 on equilibrium between lactone and carboxylate forms of 10-hydrocamptothecin in water. Polym. Chem. 4, 3245-3255 (2013).
57. Yu, L., Ci, T. Y., Zhou, S. C., Zeng, W. J. & Ding, J. D. The thermogelling PLGAPEG- PLGA block copolymer as a sustained release matrix of doxorubicin. Biomater. Sci. 1, 411-420 (2013).
58. Liu, C. D., Zhang, Z. X., Liu, K. L., Ni, X. P. & Li, J. Biodegradable thermogelling poly(ester urethane)s consisting of poly(1,4-butylene adipate), poly(ethylene glycol), and poly(propylene glycol). Soft Matter 9, 787-794 (2013).